'Nexavar rival' fails Phase IIb trial
This article was originally published in Scrip
Executive Summary
Jennerex's Phase IIb TRAVERSE study of Nexavar rival Pexa-Vec in second-line, advanced hepatocellular carcinoma (HCC; liver cancer) patients has failed to meet its primary endpoint of overall survival.